Monopar Therapeutics (NASDAQ:MNPR) Hits New 12-Month High – Time to Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $120.42 and last traded at $119.8760, with a volume of 5572 shares trading hands. The stock had previously closed at $119.23.

Analysts Set New Price Targets

Several equities research analysts have weighed in on MNPR shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, July 15th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a report on Thursday, July 23rd. BTIG Research increased their price objective on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Finally, HC Wainwright lifted their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $112.08.

Monopar Therapeutics Trading Up 4.1%

The stock has a 50-day simple moving average of $88.63 and a 200 day simple moving average of $69.35. The company has a market cap of $831.08 million, a price-to-earnings ratio of -64.79 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. As a group, research analysts forecast that Monopar Therapeutics Inc. will post -2.82 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MNPR. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the third quarter valued at $28,000. BNP Paribas Financial Markets raised its stake in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at about $65,000. JPMorgan Chase & Co. boosted its stake in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics during the second quarter worth about $80,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.